Terms: = Ovarian cancer AND ATRX, P46100, ZNF-HX, XNP, XH2, SHS, SFM1, RAD54, MRXHF1, MGC2094, ATR2, 546 AND Treatment
20 results:
1. ovarian and uterine carcinosarcomas are sensitive in vitro and in vivo to elimusertib, a novel ataxia-telangiectasia and Rad3-related (ATR) kinase inhibitor.
Manavella DD; McNamara B; Harold J; Bellone S; Hartwich TMP; Yang-Hartwich Y; Mutlu L; Zipponi M; Demirkiran C; Verzosa MS; Altwerger G; Ratner E; Huang GS; Clark M; Andikyan V; Azodi M; Schwartz PE; Dottino PR; Choi J; Alexandrov LB; Buza N; Hui P; Santin AD
Gynecol Oncol; 2023 Feb; 169():98-105. PubMed ID: 36525930
[TBL] [Abstract] [Full Text] [Related]
2. Who are the long-term survivors of recurrent ovarian carcinoma?: a retrospective analysis of a multicenter study.
Yoshihara M; Mogi K; Kitami K; Uno K; Iyoshi S; Tano S; Fujimoto H; Miyamoto E; Yoshikawa N; Emoto R; Matsui S; Kajiyama H
Int J Clin Oncol; 2022 Oct; 27(10):1660-1668. PubMed ID: 35906336
[TBL] [Abstract] [Full Text] [Related]
3. Symptom burden and quality of life with chemotherapy for recurrent ovarian cancer: the Gynecologic cancer InterGroup-Symptom Benefit Study.
Lee YC; King MT; O'Connell RL; Lanceley A; Joly F; Hilpert F; Davis A; Roncolato FT; Okamoto A; Bryce J; Donnellan P; Oza AM; Avall-Lundqvist E; Berek JS; Ledermann JA; Berton D; Sehouli J; Feeney A; Kaminsky MC; Diamante K; Stockler MR; Friedlander ML;
Int J Gynecol Cancer; 2022 Jun; 32(6):761-768. PubMed ID: 35086926
[TBL] [Abstract] [Full Text] [Related]
4. Impact of veliparib, paclitaxel dosing regimen, and germline BRCA status on the primary treatment of serous ovarian cancer - an ancillary data analysis of the VELIA trial.
Aghajanian C; Swisher EM; Okamoto A; Steffensen KD; Bookman MA; Fleming GF; Friedlander M; Moore KN; Tewari KS; O'Malley DM; Chan JK; Ratajczak C; Hashiba H; Wu M; Dinh MH; Coleman RL
Gynecol Oncol; 2022 Feb; 164(2):278-287. PubMed ID: 34930617
[TBL] [Abstract] [Full Text] [Related]
5. Relationship between ascites volume and clinical outcomes in epithelial ovarian cancer.
Quan Q; Zhou S; Liu Y; Yin W; Liao Q; Ren S; Zhang F; Meng Y; Mu X
J Obstet Gynaecol Res; 2021 Apr; 47(4):1527-1535. PubMed ID: 33506580
[TBL] [Abstract] [Full Text] [Related]
6. Precision medicine phase II study evaluating the efficacy of a double immunotherapy by durvalumab and tremelimumab combined with olaparib in patients with solid cancers and carriers of homologous recombination repair genes mutation in response or stable after olaparib treatment.
Fumet JD; Limagne E; Thibaudin M; Truntzer C; Bertaut A; Rederstorff E; Ghiringhelli F
BMC Cancer; 2020 Aug; 20(1):748. PubMed ID: 32778095
[TBL] [Abstract] [Full Text] [Related]
7. Menopausal hormone therapy treatment options and ovarian cancer risk: A Swedish prospective population-based matched-cohort study.
Simin J; Tamimi RM; Callens S; Engstrand L; Brusselaers N
Int J Cancer; 2020 Jul; 147(1):33-44. PubMed ID: 31584190
[TBL] [Abstract] [Full Text] [Related]
8. Niraparib Maintenance Therapy in Patients With Recurrent ovarian cancer After a Partial Response to the Last Platinum-Based Chemotherapy in the ENGOT-OV16/NOVA Trial.
Del Campo JM; Matulonis UA; Malander S; Provencher D; Mahner S; Follana P; Waters J; Berek JS; Woie K; Oza AM; Canzler U; Gil-Martin M; Lesoin A; Monk BJ; Lund B; Gilbert L; Wenham RM; Benigno B; Arora S; Hazard SJ; Mirza MR
J Clin Oncol; 2019 Nov; 37(32):2968-2973. PubMed ID: 31173551
[TBL] [Abstract] [Full Text] [Related]
9. Neoadjuvant chemotherapy versus debulking surgery in advanced tubo-ovarian cancers: pooled analysis of individual patient data from the EORTC 55971 and CHORUS trials.
Vergote I; Coens C; Nankivell M; Kristensen GB; Parmar MKB; Ehlen T; Jayson GC; Johnson N; Swart AM; Verheijen R; McCluggage WG; Perren T; Panici PB; Kenter G; Casado A; Mendiola C; Stuart G; Reed NS; Kehoe S; ;
Lancet Oncol; 2018 Dec; 19(12):1680-1687. PubMed ID: 30413383
[TBL] [Abstract] [Full Text] [Related]
10. Small cell carcinoma of the ovary-hypercalcemic type (SCCOHT): A review of 47 cases.
Callegaro-Filho D; Gershenson DM; Nick AM; Munsell MF; Ramirez PT; Eifel PJ; Euscher ED; Marques RM; Nicolau SM; Schmeler KM
Gynecol Oncol; 2016 Jan; 140(1):53-7. PubMed ID: 26546963
[TBL] [Abstract] [Full Text] [Related]
11. Survivors of gynecologic malignancies: impact of treatment on health and well-being.
Westin SN; Sun CC; Tung CS; Lacour RA; Meyer LA; Urbauer DL; Frumovitz MM; Lu KH; Bodurka DC
J Cancer Surviv; 2016 Apr; 10(2):261-70. PubMed ID: 26245979
[TBL] [Abstract] [Full Text] [Related]
12. Pathological and prognostic significance of matrix metalloproteinase-2 expression in ovarian cancer: a meta-analysis.
Liu C
Clin Exp Med; 2016 Aug; 16(3):375-82. PubMed ID: 26123901
[TBL] [Abstract] [Full Text] [Related]
13. [Expression and significance of heparin binding-epidermal growth factor-like growth factor in paclitaxel-resistant ovarian cancer].
Tang X; Lu M; Li C; Deng S; Li M
Zhonghua Fu Chan Ke Za Zhi; 2014 Jul; 49(7):517-22. PubMed ID: 25327734
[TBL] [Abstract] [Full Text] [Related]
14. ovarian cancer surgery: health and coping during the perioperative period.
Seibaek L; Blaakaer J; Petersen LK; Hounsgaard L
Support Care Cancer; 2013 Feb; 21(2):575-82. PubMed ID: 22875414
[TBL] [Abstract] [Full Text] [Related]
15. Hyperthermic intraperitoneal chemotherapy added to the treatment of ovarian cancer. A review of achieved results and complications.
Dovern E; de Hingh IH; Verwaal VJ; van Driel WJ; Nienhuijs SW
Eur J Gynaecol Oncol; 2010; 31(3):256-61. PubMed ID: 21077465
[TBL] [Abstract] [Full Text] [Related]
16. [Biomarker in gynecologic malignancies].
Isonishi S
Gan To Kagaku Ryoho; 2004 Jul; 31(7):1003-7. PubMed ID: 15272576
[TBL] [Abstract] [Full Text] [Related]
17. The case of the elusive androgen.
Cobin RH
Endocr Pract; 2002; 8(6):433-8. PubMed ID: 15260009
[TBL] [Abstract] [Full Text] [Related]
18. Evaluating the total costs of chemotherapy-induced toxicity: results from a pilot study with ovarian cancer patients.
Calhoun EA; Chang CH; Welshman EE; Fishman DA; Lurain JR; Bennett CL
Oncologist; 2001; 6(5):441-5. PubMed ID: 11675522
[TBL] [Abstract] [Full Text] [Related]
19. Hormones and hormone antagonists: mechanisms of action in carcinogenesis of endometrial and breast cancer.
Flötotto T; Djahansouzi S; Gläser M; Hanstein B; Niederacher D; Brumm C; Beckmann MW
Horm Metab Res; 2001 Aug; 33(8):451-7. PubMed ID: 11544557
[TBL] [Abstract] [Full Text] [Related]
20. [Cisplatin, vinblastine, and bleomycin combination chemotherapy in a stage IV pure endodermal sinus tumor of the ovary--a case report of a long-term survival].
Saito N; Kashimura Y; Soh T; Tsukamoto N
Gan No Rinsho; 1988 Dec; 34(15):2114-8. PubMed ID: 2466134
[TBL] [Abstract] [Full Text] [Related]
